Improving the affinity of SL0101 for RSK using structure-based design. - Wikidata - awgldk - TriplyDB

Improving the affinity of SL0101 for RSK using structure-based design.

Improving the affinity of SL0101 for RSK using structure-based design.

http://www.wikidata.org/entity/Q30421848

about

Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.Bacterial Expression, Purification and In Vitro Phosphorylation of Full-Length Ribosomal S6 Kinase 2 (RSK2)Ribosomal S6 kinase (RSK) modulators: a patent review.RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival De Novo Synthesis of Mono- and Oligosaccharides via Dihydropyran Intermediates.De novo synthesis and biological evaluation of C6″-substituted C4″-amide analogues of SL0101.Total synthesis of tetrahydrolipstatin and stereoisomers via a highly regio- and diastereoselective carbonylation of epoxyhomoallylic alcohols.Synthesis and Structure-Activity Relationship Study of 5a-Carbasugar Analogues of SL0101.

P2860

Q30275521-652B6BCC-8A48-4F02-AF63-39080ED9F992 Q30275748-47E149CE-E94B-447B-872E-F32FBAED3073 Q38895271-569840E9-4AEC-4138-8DD4-084D9579F0EA Q38959778-A8BDAC5F-DEE5-4C6F-84EA-22585B61D32C Q39187945-CE9E0F2C-81AF-4269-B736-2B92A8360C74 Q41849111-5AE0B632-43DD-4F51-B2CB-7C2D4AA66827 Q42147079-5AA34D19-8740-40C4-AD9D-428FBC64FAA3 Q42241935-5DC04404-E06B-48BD-86AF-A4884BDFA8A8

P2860

Improving the affinity of SL0101 for RSK using structure-based design.

http://www.wikidata.org/entity/Q30421848

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Improving the affinity of SL0101 for RSK using structure-based design.

@ast

Improving the affinity of SL0101 for RSK using structure-based design.

@en

type

label

Improving the affinity of SL0101 for RSK using structure-based design.

@ast

Improving the affinity of SL0101 for RSK using structure-based design.

@en

prefLabel

Improving the affinity of SL0101 for RSK using structure-based design.

@ast

Improving the affinity of SL0101 for RSK using structure-based design.

@en

P1433

Q30421848-ABF9B5D7-91B6-4759-A122-0FFCCCC59FE4

P1476

Q30421848-2316F2AE-B601-4196-B142-BF35BE52C3D3

P2093

Q30421848-757F1018-E6BE-44DB-B9E5-40469629FC3E

Q30421848-80259CD3-CA6A-4BE4-960C-41CA496DB619

Q30421848-9512064D-A50E-4F5C-A9C2-8CFC46ED634E

Q30421848-9E35F403-48BE-45A2-B1AC-4B73AB7F4C25

Q30421848-AC1061FB-65F5-4AF2-B967-F41C8769B1FD

Q30421848-CDFB1465-BB1E-4C6E-A6BA-F6201F0052F3

Q30421848-E578EAC8-644F-4975-A98F-E936BFB48001

P2860

Q30421848-0D7BCE88-376D-40D7-86E4-353F9581AAB8

Q30421848-0F747924-E3CD-4C96-819F-4CE417F38FA3

Q30421848-0FD40513-C640-4B8B-8CA3-D2DA3332CAE5

Q30421848-11B4FBDC-3193-430F-B4FE-10D36AE0E4B8

Q30421848-16587CF3-CFEE-4643-96A5-91B2EACE7648

Q30421848-2FA0408E-BF63-4BB2-AE35-B2BAE92339B4

Q30421848-38DC57E9-BAE2-4DD7-8F07-6FD4F3131E4E

Q30421848-3ACD953B-499E-4EBC-9DE8-D38E132FD397

Q30421848-4D616428-F070-4A34-8929-D4C62650D6F7

Q30421848-53DFA8FC-F747-4894-8906-AFA13FAF74F5

P304

Q30421848-AB6D2C42-9F2F-4BFF-8266-1C2B8E101BEC

P31

Q30421848-306A8794-B21A-4686-B7A4-29B2795C8C69

P356

Q30421848-B198410F-70EB-4067-8E01-F93953CD57F1

P433

Q30421848-C804C6F5-BE4D-434E-94C4-9425C067B5EE

P478

Q30421848-35257956-84F9-460A-B128-231B9355EF7E

P50

Q30421848-29A40CC6-4E28-412B-9589-87F1F40AB1BB

Q30421848-378907BC-D914-42DF-B574-8FBE5B2166CF

Q30421848-5A5D7584-E7F3-45F8-A45E-09A2088003D4

P577

Q30421848-593DDA38-FB4E-4D33-AF29-2EDB098B513F

P5875

Q30421848-ABA97CE6-8AF7-4DD5-961E-63693481F30C

P698

Q30421848-C8254149-3DED-410A-92C4-5C60325AD110

P932

Q30421848-10BB1CDE-CA14-4F66-B4D4-9C1AC539807E

P356

P1433

ACS Medicinal Chemistry Letters

P1476

Improving the affinity of SL0101 for RSK using structure-based design

@en

P2093

Benjamin R Schroeder

http://www.w3.org/2001/XMLSchema#string

David E Clark

http://www.w3.org/2001/XMLSchema#string

Michael K Hilinski

http://www.w3.org/2001/XMLSchema#string

Qi Zhang

http://www.w3.org/2001/XMLSchema#string

Rajender Vemula

http://www.w3.org/2001/XMLSchema#string

Roman M Mrozowski

http://www.w3.org/2001/XMLSchema#string

Sidney M Hecht

http://www.w3.org/2001/XMLSchema#string

P2860

An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis

The RSK family of kinases: emerging roles in cellular signalling

Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase.

The selectivity of protein kinase inhibitors: a further update

Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.

A Direct Comparison of the Anticancer Activities of Digitoxin MeON-Neoglycosides and O-Glycosides: Oligosaccharide Chain Length-Dependent Induction of Caspase-9-Mediated Apoptosis

Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability.

RSK in tumorigenesis: connections to steroid signaling.

Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.

Synthesis of a potent and selective inhibitor of p90 Rsk.

P304

175-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ML300298V

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

George A O'Doherty

Deborah A. Lannigan

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236071612

http://www.w3.org/2001/XMLSchema#string

P698

23519677

http://www.w3.org/2001/XMLSchema#string

P932

3601785

http://www.w3.org/2001/XMLSchema#string